📊 CRMD Key Takeaways
Is CorMedix Inc. (CRMD) a Good Investment?
CorMedix demonstrates exceptional fundamental strength with 617% revenue growth, outstanding profitability margins (82.5% gross, 50% operating, 30.3% net), and fortress-like financial health (zero debt, $178M cash, 2.98x current ratio). Strong free cash flow generation (32.7% FCF margin) and sustainable operating leverage validate earnings quality, though extraordinary growth rates and low ROE/ROA metrics warrant monitoring for sustainability.
CorMedix shows exceptional fundamental momentum, with revenue up 617% year over year and net income up over 1000%, while sustaining very high gross, operating, and net margins. The balance sheet is healthy, with strong liquidity, no meaningful leverage, and free cash flow conversion that supports continued commercialization and operating flexibility. The main question is whether this unusually strong profitability and growth level is durable rather than a one-period surge.
CorMedix Inc. Key Strengths (CRMD)
- Exceptional YoY revenue growth of 617% with 780% EPS growth demonstrating strong operating leverage
- Outstanding profitability: 82.5% gross margin, 50% operating margin, 30.3% net margin with $38.6M net income
- Fortress balance sheet: zero long-term debt, $178.1M cash, 2.98x current ratio, 0.00 debt/equity ratio
- High-quality earnings: 32.7% free cash flow margin with minimal capex ($729K) shows cash generation efficiency
- Explosive top-line and bottom-line growth, with revenue reaching $311.71M and net income $163.06M
- Outstanding profitability, including 88.5% gross margin, 48.2% operating margin, and 52.3% net margin
- Strong financial health, with $144.84M in cash, a 2.11x current ratio, debt-free leverage, and $172.79M in free cash flow
CRMD Stock Risks: CorMedix Inc. Investment Risks
- Sustainability risk: 617% revenue growth is extraordinarily high and may not be repeatable in future periods
- Capital efficiency concern: despite high margins, ROE of 8.8% and ROA of 4.7% suggest inefficient asset/equity deployment
- No insider buying activity in last 90 days (0 Form 4 filings) could indicate mixed management conviction
- Pharmaceutical sector competition and regulatory risks inherent to SIC 2834 industry
- Growth may normalize sharply after an exceptionally high year-over-year expansion period
- Pharmaceutical fundamentals can be volatile if revenue is concentrated in a limited product base or launch cycle
- Current profitability may prove difficult to sustain if operating costs, competitive pressure, or commercialization spending rise
Key Metrics to Watch
- Gross margin sustainability and potential compression from current 82.5% level in future quarters
- Revenue growth deceleration rate - critical to assess if 617% can be maintained or normalizes significantly
- Return on Equity (ROE) trend and management's capital allocation strategy to improve utilization efficiency
- Operating cash flow consistency and free cash flow margin maintenance as revenue normalizes
- Product concentration and new revenue drivers - confirm growth is diversified, not single-product dependent
- Revenue growth and net margin durability over the next several filings
- Operating cash flow and free cash flow conversion relative to earnings
CorMedix Inc. (CRMD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 32.7% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 2.98x current ratio provides a solid financial cushion.
CRMD Profit Margin, ROE & Profitability Analysis
CRMD vs Healthcare Sector: How CorMedix Inc. Compares
How CorMedix Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is CorMedix Inc. Stock Overvalued? CRMD Valuation Analysis 2026
Based on fundamental analysis, CorMedix Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
CorMedix Inc. Balance Sheet: CRMD Debt, Cash & Liquidity
CRMD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: CorMedix Inc.'s revenue has grown significantly by 130,196% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.30 indicates the company is currently unprofitable.
CRMD Revenue Growth, EPS Growth & YoY Performance
CRMD Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $39.1M | $20.6M | $0.30 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CorMedix Inc. Dividends, Buybacks & Capital Allocation
CRMD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for CorMedix Inc. (CIK: 0001410098)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CRMD
What is the AI rating for CRMD?
CorMedix Inc. (CRMD) has a Combined AI Grade of A from Claude (A) and ChatGPT (A) with 82% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CRMD's key strengths?
Claude: Exceptional YoY revenue growth of 617% with 780% EPS growth demonstrating strong operating leverage. Outstanding profitability: 82.5% gross margin, 50% operating margin, 30.3% net margin with $38.6M net income. ChatGPT: Explosive top-line and bottom-line growth, with revenue reaching $311.71M and net income $163.06M. Outstanding profitability, including 88.5% gross margin, 48.2% operating margin, and 52.3% net margin.
What are the risks of investing in CRMD?
Claude: Sustainability risk: 617% revenue growth is extraordinarily high and may not be repeatable in future periods. Capital efficiency concern: despite high margins, ROE of 8.8% and ROA of 4.7% suggest inefficient asset/equity deployment. ChatGPT: Growth may normalize sharply after an exceptionally high year-over-year expansion period. Pharmaceutical fundamentals can be volatile if revenue is concentrated in a limited product base or launch cycle.
What is CRMD's revenue and growth?
CorMedix Inc. reported revenue of $127.4M.
Does CRMD pay dividends?
CorMedix Inc. does not currently pay dividends.
Where can I find CRMD SEC filings?
Official SEC filings for CorMedix Inc. (CIK: 0001410098) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CRMD's EPS?
CorMedix Inc. has a diluted EPS of $0.43.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is CRMD's fundamental grade?
Based on our AI fundamental analysis in June 2026, CorMedix Inc. has a A grade with 82% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CRMD stock overvalued or undervalued?
Valuation metrics for CRMD: ROE of 8.8% (sector avg: 15%), net margin of 30.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is CRMD's AI grade for 2026?
Our dual AI analysis gives CorMedix Inc. a combined A grade for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CRMD's free cash flow?
CorMedix Inc.'s operating cash flow is $42.4M, with capital expenditures of $729.0K. FCF margin is 32.7%.
How does CRMD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 30.3% (avg: 12%), ROE 8.8% (avg: 15%), current ratio 2.98 (avg: 2).